These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 26071799)

  • 1. Dual drug delivery from vitamin E loaded contact lenses for glaucoma therapy.
    Hsu KH; Carbia BE; Plummer C; Chauhan A
    Eur J Pharm Biopharm; 2015 Aug; 94():312-21. PubMed ID: 26071799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended drug delivery by contact lenses for glaucoma therapy.
    Peng CC; Burke MT; Carbia BE; Plummer C; Chauhan A
    J Control Release; 2012 Aug; 162(1):152-8. PubMed ID: 22721817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug delivery by contact lens in spontaneously glaucomatous dogs.
    Peng CC; Ben-Shlomo A; Mackay EO; Plummer CE; Chauhan A
    Curr Eye Res; 2012 Mar; 37(3):204-11. PubMed ID: 22335807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of topical administration of a fixed combination of dorzolamide-timolol to monotherapy with timolol or dorzolamide on IOP, pupil size, and heart rate in glaucomatous dogs.
    Plummer CE; MacKay EO; Gelatt KN
    Vet Ophthalmol; 2006; 9(4):245-9. PubMed ID: 16771760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients.
    Renieri G; Führer K; Scheithe K; Lorenz K; Pfeiffer N; Thieme H
    J Ocul Pharmacol Ther; 2010 Dec; 26(6):597-603. PubMed ID: 20977366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glaucoma therapy by extended release of timolol from nanoparticle loaded silicone-hydrogel contact lenses.
    Jung HJ; Abou-Jaoude M; Carbia BE; Plummer C; Chauhan A
    J Control Release; 2013 Jan; 165(1):82-9. PubMed ID: 23123188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.
    Tamer C; Oksüz H
    Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients.
    Janulevicienë I; Harris A; Kagemann L; Siesky B; McCranor L
    Acta Ophthalmol Scand; 2004 Dec; 82(6):730-7. PubMed ID: 15606472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A
    Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-center, 4-year, open-label study.
    Martínez A; Sánchez M
    Clin Ther; 2008 Jun; 30(6):1120-34. PubMed ID: 18640468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery.
    Maulvi FA; Lakdawala DH; Shaikh AA; Desai AR; Choksi HH; Vaidya RJ; Ranch KM; Koli AR; Vyas BA; Shah DO
    J Control Release; 2016 Mar; 226():47-56. PubMed ID: 26860285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
    Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure.
    Shin DH; Feldman RM; Sheu WP;
    Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-delivery of timolol and hyaluronic acid from semi-circular ring-implanted contact lenses for the treatment of glaucoma: in vitro and in vivo evaluation.
    Desai AR; Maulvi FA; Pandya MM; Ranch KM; Vyas BA; Shah SA; Shah DO
    Biomater Sci; 2018 May; 6(6):1580-1591. PubMed ID: 29708242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists' offices.
    Gugleta K; Orgül S; Flammer J
    Curr Med Res Opin; 2003; 19(4):330-5. PubMed ID: 12841926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies.
    Fechtner RD; McCarroll KA; Lines CR; Adamsons IA
    J Ocul Pharmacol Ther; 2005 Jun; 21(3):242-9. PubMed ID: 15969642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of latanoprost monotherapy and combined therapy of 0.5% timolol and 1% dorzolamide in chronic primary angle-closure glaucoma (CACG) in Japanese patients.
    Sakai H; Shinjyo S; Nakamura Y; Nakamura Y; Ishikawa S; Sawaguchi S
    J Ocul Pharmacol Ther; 2005 Dec; 21(6):483-9. PubMed ID: 16386090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dorzolamide and timolol saves retinal ganglion cells in glaucomatous adult rats.
    Sarup V; McEwan GC; Thompson C; Patil KA; Sharma SC
    J Ocul Pharmacol Ther; 2005 Dec; 21(6):454-62. PubMed ID: 16386087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Sezgin Akçay Bİ; Güney E; Bozkurt KT; Unlü C; Akçali G
    J Ocul Pharmacol Ther; 2013 Dec; 29(10):882-6. PubMed ID: 24180628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
    Hatanaka M; Reis A; Sano ME; Susanna R
    J Glaucoma; 2010; 19(5):331-5. PubMed ID: 19730119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.